Metabo-oncology, which focuses on the link between cancer and metabolic hormone dysfunction, is poised to spark a paradigm shift in cancer treatment. The leader in this emerging field isn’t some big pharma. Rather, it’s a clever and persistent company based in Cambridge, Massachusetts, called SynDevRx.
First, it was chemotherapy alone. Then came targeted therapies. Most recently, we’ve seen the advent of immuno-oncology, which has taught us that cancer involves multiple biologic systems across the whole body. At SynDevRx, we believe metabo-oncology is the next major advancement in cancer treatment. What is metabo-oncology? Basically, it’s an area of research focused on the connection between cancer and metabolic hormone dysfunction (which is typical in overweight and obese people).
Rates of six different cancers that are associated with obesity increased among adults ages 25-49 between 1995 and 2014, according to the research, which was published in the journal Lancet Public Health and based on information in the Cancer in North America database. These cancers include multiple myeloma, colorectal, endometrial, gallbladder, kidney and pancreatic.
E: [email protected]